InflaRx Buy Rating Backed by Promising Drug Prospects and Financial Stability
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Krystal Biotech (KRYS) and InflaRx (IFRX)
InflaRx Buy Rating Affirmed: Financial Stability and Gohibic's Market Potential
HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target
InflaRx Analyst Ratings
InflaRx Analyst Ratings
InflaRx's Promising Future: Buy Rating Reaffirmed Amidst Pipeline Progress and Upcoming R&D Insights
InflaRx Analyst Ratings
HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target
InflaRx Buy Rating: Strong Financials and High Potential of Gohibic for PG Treatment
LifeSci Capital Remains a Hold on InflaRx (IFRX)
LifeSci Capital Reaffirms Their Hold Rating on InflaRx (IFRX)
InflaRx Analyst Ratings
Buy Rating Justified for InflaRx Despite Earnings Miss: Financial Stability and INF904's Market Potential
InflaRx Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), InflaRx (IFRX) and Eli Lilly & Co (LLY)
InflaRx's Promising INF904 Phase 1 Results Prompt Buy Rating
InflaRx (IFRX) Gets a Hold From LifeSci Capital
Buy Rating for InflaRx: Potential Breakthrough PG Treatment and Promising Revenue Forecasts
Analysts Have Conflicting Sentiments on These Healthcare Companies: InflaRx (IFRX), Exelixis (EXEL) and Humana (HUM)
No Data